For example, an inhibitor of the histone methyltransferase DOT1L which reverses HOX/MEIS activation in AML was found to have modest efficacy in a clinical trial for patients with MLL-rearranged AML. The gene discussed is PRDM9; the disease is acute myeloid leukemia.